NHTC · Natural Health Trends Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $39.78M | $42.96M | $43.92M | $49.13M | $60.01M | $62.07M |
| Cost of Revenue | $10.52M | $11.18M | $11.18M | $12.66M | $15.01M | $16.99M |
| Gross Profit | $29.25M | $31.79M | $32.75M | $36.47M | $44.99M | $45.08M |
| R&D | - | - | - | - | - | - |
| SG&A | $14.76M | $15.51M | $16.01M | $16.00M | $17.85M | $18.21M |
| Total Operating Expenses | $31.06M | $33.08M | $34.42M | $36.74M | $43.42M | $44.41M |
| D&A | $109.0K | $131.0K | $164.0K | $204.0K | $299.0K | $410.0K |
| Operating Income | ($1.81M) | ($1.30M) | ($1.67M) | ($270.0K) | $1.57M | $669.0K |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $315.0K | $48.0K | $177.0K | $289.0K | $425.0K | $647.0K |
| Net Income | ($882.0K) | $572.0K | $568.0K | $313.0K | $1.08M | $843.0K |
| EPS - Basic | ($0.08) | $0.05 | $0.05 | $0.03 | $0.10 | $0.08 |
| EPS - Diluted | ($0.08) | $0.05 | $0.05 | $0.03 | $0.09 | $0.07 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.81M | $13.53M | $56.18M | $69.67M | $83.84M | $92.37M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | $2.05M | $3.27M | $4.29M | $4.53M | $5.26M | $3.78M |
| Accounts Payable | $555.0K | $895.0K | $990.0K | $810.0K | $761.0K | $580.0K |
| Current Assets | $34.19M | $50.98M | $64.23M | $77.55M | $93.47M | $99.74M |
| Total Assets | $38.43M | $55.36M | $69.09M | $82.82M | $98.36M | $105.94M |
| Current Liabilities | $13.69M | $20.80M | $19.98M | $20.44M | $24.66M | $21.51M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $15.00M | $22.49M | $27.49M | $32.67M | $38.87M | $38.24M |
| Stockholders' Equity | $23.43M | $32.87M | $41.60M | $50.15M | $59.49M | $67.70M |
| Retained Earnings | ($36.44M) | ($26.34M) | ($17.70M) | ($9.06M) | ($231.0K) | $7.82M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($6.00M) | ($3.37M) | ($4.28M) | ($4.85M) | $1.02M | $1.89M |
| Investing Cash Flow | $8.15M | ($30.07M) | ($46.0K) | ($143.0K) | ($225.0K) | ($211.0K) |
| Financing Cash Flow | ($9.21M) | ($9.21M) | ($9.21M) | ($9.14M) | ($9.14M) | ($9.14M) |
| CapEx | $68.0K | $57.0K | $46.0K | $143.0K | $225.0K | $211.0K |
| Free Cash Flow | ($6.07M) | ($3.42M) | ($4.32M) | ($5.00M) | $791.0K | $1.67M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 73.5% | 74.0% | 74.6% | 74.2% | 75.0% | 72.6% |
| Operating margin | -4.5% | -3.0% | -3.8% | -0.5% | 2.6% | 1.1% |
| EBITDA margin | -4.3% | -2.7% | -3.4% | -0.1% | 3.1% | 1.7% |
| Net margin | -2.2% | 1.3% | 1.3% | 0.6% | 1.8% | 1.4% |
| Free cash flow margin | -15.2% | -8.0% | -9.8% | -10.2% | 1.3% | 2.7% |
| FCF / Net income | 6.88 | -5.99 | -7.61 | -15.96 | 0.73 | 1.99 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 37.1% | 36.1% | 36.4% | 32.6% | 29.7% | 29.3% |
| Effective tax rate | - | 7.7% | 23.8% | 48.0% | 28.1% | 43.4% |
| Return on assets | -2.3% | 1.0% | 0.8% | 0.4% | 1.1% | 0.8% |
| Return on equity | -3.8% | 1.7% | 1.4% | 0.6% | 1.8% | 1.2% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.50 | 2.45 | 3.21 | 3.79 | 3.79 | 4.64 |
| Quick ratio | 2.35 | 2.29 | 3.00 | 3.57 | 3.58 | 4.46 |
| Cash ratio | 0.50 | 0.65 | 2.81 | 3.41 | 3.40 | 4.29 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.64 | 1.68 | 1.66 | 1.65 | 1.65 | 1.56 |
| Liabilities / Assets | 0.39 | 0.41 | 0.40 | 0.39 | 0.40 | 0.36 |
| Efficiency | ||||||
| Asset turnover | 1.04 | 0.78 | 0.64 | 0.59 | 0.61 | 0.59 |
| Inventory turnover | 5.14 | 3.42 | 2.60 | 2.80 | 2.86 | 4.50 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 71d | 107d | 140d | 130d | 128d | 81d |
| Days payable outstanding | 19d | 29d | 32d | 23d | 19d | 12d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -7.4% | -2.2% | -10.6% | -18.1% | -3.3% | -20.0% |
| Revenue CAGR (3y) | -6.8% | -10.5% | -10.9% | -14.1% | -32.8% | - |
| Revenue CAGR (5y) | -8.5% | -11.2% | -26.0% | - | - | - |
| Gross profit growth (YoY) | -8.0% | -2.9% | -10.2% | -18.9% | -0.2% | -21.6% |
| Operating income growth (YoY) | -39.2% | 22.3% | -518.9% | - | 134.8% | - |
| Net income growth (YoY) | - | 0.7% | 81.5% | -71.2% | 28.7% | - |
| EPS growth (YoY) | - | 0.0% | 66.7% | -66.7% | 28.6% | - |
| EPS CAGR (3y) | - | -17.8% | -10.6% | - | -68.0% | -67.8% |
| EPS CAGR (5y) | - | - | -55.1% | -57.2% | -54.9% | -55.1% |
| FCF growth (YoY) | -77.1% | 20.8% | 13.4% | - | -52.7% | - |
| FCF CAGR (5y) | - | - | - | - | -56.7% | -53.9% |
| Book value growth (YoY) | -28.7% | -21.0% | -17.1% | -15.7% | -12.1% | -9.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$39.78M totalPrimary Reporting Segment$38.39M · 96.5%
China Segment$946.0K · 2.4%
Russia And Kazakhstan Segment$444.0K · 1.1%
Product / service
$40.10M totalProduct$39.02M · 97.3%
Administrative Fees Freight And Other$1.08M · 2.7%
Geographic
$39.78M totalHK$32.67M · 82.1%
TW$1.54M · 3.9%
Peru And Colombia$1.21M · 3.0%
US$1.15M · 2.9%
CN$946.0K · 2.4%
Europe$530.0K · 1.3%
Other Foreign Countries$477.0K · 1.2%
CA$475.0K · 1.2%
Russia And Kazakhstan$444.0K · 1.1%
JP$333.0K · 0.8%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.12
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Wholesale-Miscellaneous Nondurable Goods
Comparing NATURAL HEALTH TRENDS CORP against the 4 most active filers in the same SIC group.